FNP Certification Exam Review Sale - now only $44.95 + Free Shipping. Fast checkout with Amazon Pay! Shop Now

SITC’s Guide to Managing Immunotherapy Toxicity

Double click on above image to view full picture

Zoom Out
Zoom In
Read a Sample Chapter
New Edition

SITC’s Guide to Managing Immunotherapy Toxicity

SKU# 9780826172143


  • Marc Ernstoff MD
  • Igor Puzanov MD, MSCI, FACP
  • Caroline Robert MD, PhD
  • Adi Diab MD
  • Peter Hersey MD, PhD
Now available on:


The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers.

With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care.

Key Features:

  • Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy
  • Provides numerous tables that condense and highlight pertinent information for quick reference
  • Describes the various clinical presentations and toxic reactions caused by immunotherapy
  • Purchase includes access to the eBook for use on most mobile devices or computer

Product Details 

  • Publication Date March 20, 2019
  • Page Count 273
  • Product Form Paperback / softback
  • ISBN 13 9780826172143
  • EISBN 9780826172150

Table of Contents 



Part 1: Immune Checkpoint Inhibitors in the Clinic

Chapter One: Overview of Anti-CTLA-4 Agents: Ipilimumab and Tremilimumab

  • Daniel Hartman Johnson and Jianjun Gao
  • Chapter Two: Overview of PD-1 and PD-L1 Inhibitors

  • Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas
  • Chapter Three: Indications and Toxicities of Immune Checkpoint Inhibitor Combinations

  • Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber

    Part 2: Specific Immune Checkpoint Inhibitor Toxicities

    Chapter Four: General Principles of Immune-Related Toxicities

  • Osama E. Rahma and Patrick A. Ott

    Chapter Five: Dermatological Toxicities: Rash, Mucosal Irritation, and Pruritus

  • Jennifer Wu and Mario E. Lacouture

    Chapter Six: Musculoskeletal and Rheumatologic Toxicities

  • Noha Abdel-Wahab, Clifton O. Bingham III, and Maria Suarez-Almazor

    Chapter Seven: Immune-Related Gastrointestinal Toxicities

  • Hamzah Abu-Sbeih, Daniel Johnson, Yinghong Wang

    Chapter Eight: Pneumotoxicity Associated with Immune Checkpoint Blockades

  • Vickie R. Shannon

    Chapter Nine: Immune-Related Endocrinopathies Associated with Immune Checkpoint Inhibitors

  • Rajeev Sharma, Ha Nguyen, Ramona Dadu

    Chapter Ten: Neurologic Adverse Events and Neurologic Complications

  • Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, Camilo Fadul

    Chapter Eleven: Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors

  • Pankit Vachhani, Igor Puzanov, Javid J. Moslehi

    Chapter Twelve: Renal Toxicities Associated with Immune Checkpoint Inhibitors

  • Ala Abudayyeh, Maen Abdelrahim, Laurence Albiges

    Chapter Thirteen: Hematologic Toxicities of Apparent Immune-Related Origins

  • George L. Chen, Caroline Robert, Alexander M. Lesokhin

    Chapter Fourteen: Ocular Toxicities Caused by Immune Dysregulation

  • Liliya Golas and Dimitra Skondra

    Chapter Fifteen: Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations

  • Douglas B. Johnson, Ryan Sullivan, Paolo A. Ascierto

    Chapter Sixteen: Cancer-Related Fatigue in Patients of Immune Checkpoint Inhibitor Therapy

  • Eric D. Hansen, Michelle Walter, Amy A. Case

    Chapter Seventeen: Cost Effectiveness and Financial Toxicity in New Cancer Therapies

  • Christine Kohn, Natalia Shcherbakova, Alberto J. Montero